nodes	percent_of_prediction	percent_of_DWPC	metapath
Isradipine—Malaise—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Isradipine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Isradipine—Leukopenia—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Isradipine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Isradipine—Cough—Fludarabine—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Isradipine—Hypotension—Teniposide—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Isradipine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Isradipine—Arthralgia—Fludarabine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Isradipine—Discomfort—Fludarabine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Isradipine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Isradipine—Dyspnoea—Teniposide—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Isradipine—Depression—Carmustine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Isradipine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Isradipine—Oedema—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Isradipine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Isradipine—Decreased appetite—Teniposide—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Isradipine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Isradipine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Isradipine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Isradipine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Isradipine—Rash—Mechlorethamine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Isradipine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Isradipine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Isradipine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Isradipine—Flushing—Bleomycin—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Isradipine—Depression—Vincristine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Isradipine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Isradipine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Isradipine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Isradipine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Isradipine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Isradipine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Isradipine—Nausea—Mechlorethamine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Isradipine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Isradipine—Urticaria—Teniposide—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Isradipine—Paraesthesia—Fludarabine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Isradipine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Isradipine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Isradipine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Isradipine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Isradipine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Isradipine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Isradipine—Visual impairment—Carmustine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Isradipine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Isradipine—Fatigue—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Isradipine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Isradipine—Constipation—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Isradipine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Isradipine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Isradipine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Isradipine—Urethral disorder—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Isradipine—Eye disorder—Carmustine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Isradipine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Isradipine—Flushing—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Isradipine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Isradipine—Anaemia—Bleomycin—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Isradipine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Isradipine—Asthenia—Teniposide—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Isradipine—Malaise—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Isradipine—Pruritus—Teniposide—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Isradipine—Leukopenia—Bleomycin—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Isradipine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Isradipine—Mental disorder—Carmustine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Isradipine—Malnutrition—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Isradipine—Cough—Bleomycin—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Isradipine—Angiopathy—Vincristine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Isradipine—Diarrhoea—Teniposide—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Isradipine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Isradipine—Chest pain—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Isradipine—Back pain—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Isradipine—Discomfort—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Isradipine—Mental disorder—Vincristine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Isradipine—Urine output increased—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Isradipine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Isradipine—Vision blurred—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Isradipine—Oedema—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Isradipine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Isradipine—Anaemia—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Isradipine—Back pain—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Isradipine—Vomiting—Teniposide—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Isradipine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Isradipine—Asthenia—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Isradipine—Rash—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Isradipine—Dermatitis—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Isradipine—Headache—Teniposide—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Isradipine—Pruritus—Fludarabine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Isradipine—Back pain—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Isradipine—Leukopenia—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Isradipine—Anaemia—Vincristine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Isradipine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Isradipine—Polyuria—Methotrexate—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Isradipine—Hypotension—Bleomycin—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Isradipine—Diarrhoea—Fludarabine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Isradipine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Isradipine—Nausea—Teniposide—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Isradipine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Isradipine—Leukopenia—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Isradipine—Chest pain—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Isradipine—Anxiety—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Isradipine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Isradipine—Malaise—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Isradipine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Isradipine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Isradipine—Oedema—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Isradipine—Decreased appetite—Bleomycin—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Isradipine—Visual disturbance—Methotrexate—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Isradipine—Cough—Mitoxantrone—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Isradipine—Vomiting—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Isradipine—Rash—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Isradipine—Dermatitis—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Isradipine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Isradipine—Headache—Fludarabine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Isradipine—Tachycardia—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Isradipine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Isradipine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Isradipine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Isradipine—Lethargy—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Isradipine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Isradipine—Discomfort—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Isradipine—Oedema—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Isradipine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Isradipine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Isradipine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Isradipine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Isradipine—Hypotension—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Isradipine—Oedema—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Isradipine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Isradipine—Nausea—Fludarabine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Isradipine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Isradipine—Shock—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Isradipine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Isradipine—Urticaria—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Isradipine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Isradipine—Insomnia—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Isradipine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Isradipine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Isradipine—Paraesthesia—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Isradipine—Hypotension—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Isradipine—Dyspnoea—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Isradipine—Somnolence—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Isradipine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Isradipine—Decreased appetite—Carmustine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Isradipine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Isradipine—Insomnia—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Isradipine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Isradipine—Paraesthesia—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Isradipine—Constipation—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Isradipine—Breast disorder—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Isradipine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Isradipine—Decreased appetite—Vincristine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Isradipine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Isradipine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Isradipine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Isradipine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Isradipine—Fatigue—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Isradipine—Asthenia—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Isradipine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Isradipine—Constipation—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Isradipine—Pruritus—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Isradipine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Isradipine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Isradipine—Constipation—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Isradipine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Isradipine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Isradipine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Isradipine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Isradipine—Urticaria—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Isradipine—Vomiting—Bleomycin—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Isradipine—Drowsiness—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Isradipine—Depression—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Isradipine—Rash—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Isradipine—Dermatitis—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Isradipine—Asthenia—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Isradipine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Isradipine—Asthenia—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Isradipine—Diarrhoea—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Isradipine—Nausea—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Isradipine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Isradipine—Dizziness—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Isradipine—Diarrhoea—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Isradipine—Hepatitis—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Isradipine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Isradipine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Isradipine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Isradipine—Vomiting—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Isradipine—Dizziness—Vincristine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Isradipine—Rash—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Isradipine—Dermatitis—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Isradipine—Visual impairment—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Isradipine—Headache—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Isradipine—Eye disorder—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Isradipine—Vomiting—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Isradipine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Isradipine—Rash—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Isradipine—Dermatitis—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Isradipine—Headache—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Isradipine—Nausea—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Isradipine—Angiopathy—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Isradipine—Vomiting—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Isradipine—Immune system disorder—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Isradipine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Isradipine—Rash—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Isradipine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Isradipine—Headache—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Isradipine—Mental disorder—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Isradipine—Malnutrition—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Isradipine—Nausea—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Isradipine—Nausea—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Isradipine—Back pain—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Isradipine—Vision blurred—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Isradipine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Isradipine—Anaemia—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Isradipine—Malaise—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Isradipine—Leukopenia—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Isradipine—Cough—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Isradipine—Arthralgia—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Isradipine—Chest pain—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Isradipine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Isradipine—Discomfort—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Isradipine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Isradipine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Isradipine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Isradipine—Skin disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Isradipine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Isradipine—Hypotension—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Isradipine—Insomnia—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Isradipine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Isradipine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Isradipine—Somnolence—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Isradipine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Isradipine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Isradipine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Isradipine—Fatigue—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Isradipine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Isradipine—Urticaria—Methotrexate—lymphatic system cancer	0.000998	0.000998	CcSEcCtD
Isradipine—Asthenia—Methotrexate—lymphatic system cancer	0.000901	0.000901	CcSEcCtD
Isradipine—Pruritus—Methotrexate—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Isradipine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000859	0.000859	CcSEcCtD
Isradipine—Dizziness—Methotrexate—lymphatic system cancer	0.000831	0.000831	CcSEcCtD
Isradipine—Vomiting—Methotrexate—lymphatic system cancer	0.000799	0.000799	CcSEcCtD
Isradipine—Rash—Methotrexate—lymphatic system cancer	0.000792	0.000792	CcSEcCtD
Isradipine—Dermatitis—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Isradipine—Headache—Methotrexate—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Isradipine—Nausea—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
